newsfilter
← Latest News
GlobeNewswire·

Passage Bio Reports Second Quarter 2023 Financial Results and Provides Recent Business Highlights

Reported promising interim data from Cohorts 1-4 in the Imagine-1 clinical trial for GM1 gangliosidosis (GM1); PBGM01 continued to have a favorable safety profile and dose-dependent effects on key CSF biomarkersDose 2 of